Evogene Officially Opens Research and Development Facility in St. Louis, Missouri
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Evogene Ltd. (EVGN) Expects Delayed Evofuel commercialization; Piper Jaffray Cuts Price Target to $8
November 19, 2015 8:56 AM ESTPiper Jaffray reiterated a Neutral rating on Evogene Ltd (NYSE: EVGN), and cut the price target to $8.00 (from $12.00), following the company's 3Q earnings report .Evogene announced results relatively in-line with Piper Jaffray's expectations, where revenue and opex were only slightly higher due to more gene discovery being done in-house. Management now expects Evofuel commercialization to be delayed,... More
